Tectonic Therapeutic, Inc. TECX | NASDAQ
|2026-08-31
Company Overview:
8.4 Year TECX Performance Metrics:
Build Custom Charts
TECX Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for TECX
Based on past 8.4-year performance, here are TECX growth metrics:
Share price CAGR of -28.98%
Dividend CAGR of +0%
Using TECX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| TECX (DRIP) | TECX - No DRIP | |
|---|---|---|
| Current Price | $21.14 | $21.14 |
| Start Shares | 473.04 | 473.04 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 473.04 | 473.04 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $0.69 | $21.14 |
| Total Dividends | $0 | $0 |
| Final Value | $327 | $10,000 |
NOTE: Above numbers are our estimate based on TECX's Dividend and Price CAGR over past 8.4 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Tectonic Therapeutic, Inc. (TECX) had its IPO on , and is traded on NASDAQ stock exchange.
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G protein-coupled receptors, or GPCRs. Its work centers on the GEODe platform, which is designed to support the development of GPCR-targeted biologic medicines for diseases where traditional approaches have been difficult to advance. The company’s current pipeline includes programs aimed at cardiovascular, fibrotic, and rare disease areas, including candidates such as TX45 and TX2100. Tectonic Therapeutic, Inc. operates in the broader drug discovery and biologics segment, where GPCR biology is an important but technically challenging area of therapeutic innovation. Based in Watertown, Massachusetts, the company focuses on advancing specialized protein and antibody-based medicines for current unmet medical needs.
TECX website: https://tectonictx.com
DCF Model — TECX
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
| Year | FCF | Implied price |
|---|
